Physician profile
John Morrison
NPI 1396936936
$16,913.98
in general payments reported to CMS, 2019-2025
30 companies · $95.54 in 2025
The $95.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.53 · 2020: $13K · 2021: $13.89 · 2022: $960 · 2023: $1,425 · 2024: $1,378 · 2025: $95.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,996.64 | 2020 | |
| Abbvie INC. | $816.39 | 2022-2024 | |
| Novo Nordisk INC | $734.72 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $404.70 | 2022-2024 | |
| Abbott Laboratories | $401.86 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $236.12 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $167.40 | 2022-2024 | |
| Dexcom, INC. | $137.36 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $123.32 | 2023 | Interstim |
| Stryker Corporation | $95.54 | 2025 | Core |
| Glaxosmithkline, LLC. | $89.06 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.82 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $60.42 | 2022 | |
| Exact Sciences Corporation | $58.38 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $56.85 | 2023-2024 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.06 | 2021-2024 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $54.53 | 2022-2024 | Contrave |
| Astrazeneca Pharmaceuticals Lp | $54.05 | 2024 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $41.84 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $38.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.19 | 2023-2024 | Xifaxan |
| Lucid Diagnostics INC. | $31.59 | 2022-2023 | |
| Daiichi Sankyo INC. | $26.33 | 2024 | Injectafer |
| Biotronik INC. | $26.28 | 2019 | |
| Cranial Technologies, INC | $19.68 | 2022 | |
| Hologic Sales and Service, LLC | $18.15 | 2022 | |
| Mannkind Corporation | $17.59 | 2022 | |
| Nevro Corp. | $14.84 | 2023 | Senza |
| Becton, Dickinson and Company | $14.30 | 2022 | |
| Sumitomo Pharma America, INC. | $13.41 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.